BioParity.UFO / UAP research

27 sources for “Research limitations”

Results

ArticleS7605

ALL-DOMAIN ANOMALY RESOLUTION OFFICE HOSTS PRIVATE WORKSHOP WITH CIVILIAN RESEARCHERS, UNIVERSITIES, AND GOVERNMENT AGENCIES

Chrissy Newton. The Debrief. February 26, 2026.

Newton reports on a private AARO/AUI workshop about UAP data practices, relaying unnamed participants’ impressions and quoted responses from spokesperson Sue Gough. Privacy conditions, recommendations and perceived collaboration do not establish classified programme access or validate recovery claims.

Complete supplied reporter text; original workshop records missing
ArticleS7606

Congressional Briefing on UAP Science

Avi Loeb. avi-loeb.medium.com. April 28, 2025.

Loeb announces a planned May2025 congressional presentation, proposes new observations and offers to help analyze any government-held extrasolar information. That conditional offer originates with Loeb; it does not establish a government approach or access. Natural IM1 origins, funding contingencies and an all-human UAP outcome remain explicit possibilities.

Complete supplied public essay; planned event and original records qualified
PaperS7570

MAPS: pathologist-level cell type annotation from tissue images through machine learning

Muhammad Shaban, Yunhao Bai, Huaying Qiu, Shulin Mao, Jason Yeung, Yao Yu Yeo, Vignesh Shanmugam, Han Chen, Bokai Zhu, Jason L Weirather, Garry P Nolan, Margaret A Shipp, Scott J Rodig, Sizun Jiang, Faisal Mahmood. ebi.ac.uk. January 2, 2024.

MAPS uses expert-labelled protein-expression data to classify cells. The authors report strong results within datasets, while acknowledging leakage risk from splitting one patient’s CODEX image by cells. Performance falls across cohorts and competing methods sometimes do better. Nolan is a coauthor and supervisor; disclosed commercial interests, reporting differences and missing original materials accompany the findings.

Complete supplied article and supplement text read; original and tiny-label gaps
PaperS7520

Highly multiplexed spatial profiling with CODEX: bioinformatic analysis and application in human disease

Wilson Kuswanto, Garry Nolan, Guolan Lu. ebi.ac.uk. November 21, 2022.

This narrative review explains CODEX tissue imaging, processing limitations and spatial analysis. Its disease examples summarize cited studies; they do not supply a new patient cohort or independent replication. The review calls for stronger causal and prospective validation.

Supplied review text and qualified figures read
PaperS7620

Nanoscopic subcellular imaging enabled by ion beam tomography

Ahmet F Coskun, Guojun Han, Shambavi Ganesh, Shih-Yu Chen, Xavier Rovira Clavé, Stefan Harmsen, Sizun Jiang, Christian M Schürch, Yunhao Bai, Chuck Hitzman, Garry P Nolan. ebi.ac.uk. February 4, 2021.

The authors demonstrate destructive ion-beam imaging and computational reconstruction in fixed cells and selected tissue. Calibration resolution, localization precision and theoretical capability remain distinct. Nested depth slices and reconstruction-derived ground truth limit independence. The method is a research demonstration, with no clinical efficacy or UAP finding established.

Complete supplied main, mathematics and figures; supplements unreceived
PaperS7617

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs

Ivan T. Lee et al.. ebi.ac.uk. October 28, 2020.

The authors localize ACE2 staining to respiratory cilia and compare receptor expression across medication groups. Small subgroups, treatment indication, age imbalance and retrospective confounding qualify the comparisons. Negative or nonsignificant results do not establish equivalence, infection protection or clinical benefit. The study reports localization and expression rather than a treatment trial.

Complete supplied main, figures and two supplements; peer review unreviewed
PaperS7624

Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front

Christian M Schürch, Salil S Bhate, Graham L Barlow, Darci J Phillips, Luca Noti, Inti Zlobec, Pauline Chu, Sarah Black, Janos Demeter, David R McIlwain, Shigemi Kinoshita, Nikolay Samusik, Yury Goltsev, Garry P Nolan. ebi.ac.uk. September 3, 2020.

The authors analyze spatial immune patterns in selected colorectal-cancer tissue. Thirty-five patients supply140 dependent tissue cores; repeated cells, regions and holdouts do not create new cohorts. Survival findings and correlation-based “communication” are exploratory. A linked correction adds Shigemi Kinoshita to the author list. No clinical efficacy or UAP finding is established.

Complete supplied main, figures and correction; bounded supplementary review
PaperS7610

Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity

Lu Cui, Shih-Yu Chen, Tristan Lerbs, Jin-Wook Lee, Pablo Domizi, Sydney Gordon, Yong-hun Kim, Garry Nolan, Paola Betancur, Gerlinde Wernig. ebi.ac.uk. June 3, 2020.

The authors report JUN-associated changes in lung fibroblasts and test mechanisms and interventions in engineered cultures and mouse models. Eleven end-stage cases and three cancer-resection controls define the human comparison. Preclinical findings, sampling biases and explicit toxicity cautions prevent claims of proven treatment benefit or safety in patients.

Complete supplied main text; bounded supplemental visuals
PaperS7603

Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line

Yapeng Su, Melissa E Ko, Hanjun Cheng, Ronghui Zhu, Min Xue, Jessica Wang, Jihoon W Lee, Luke Frankiw, Alexander Xu, Stephanie Wong, Lidia Robert, Kaitlyn Takata, Dan Yuan, Yue Lu, Sui Huang, Antoni Ribas, Raphael Levine, Garry P Nolan, Wei Wei, Sylvia K Plevritis, Guideng Li, David Baltimore, James R Heath. ebi.ac.uk. May 11, 2020.

The authors infer different routes to early drug tolerance within one cultured melanoma cell line and test selected drug combinations. The inferred barrier was not measured. Negative inhibitor assays, dependence among cell snapshots and possible normal-tissue toxicity qualify the results; clinical efficacy was not established.

Complete supplied main text; partial supplemental visuals
PaperS7608

Ultra-high throughput single-cell analysis of proteins and RNAs by split-pool synthesis

Maeve O’Huallachain, Felice-Alessio Bava, Mary Shen, Carolina Dallett, Sri Paladugu, Nikolay Samusik, Simon Yu, Razika Hussein, Grantland R. Hillman, Samuel Higgins, Melanie Lou, Angelica Trejo, Laura Qin, Yu Chuan Tai, Shigemi M. Kinoshita, Astraea Jager, Deval Lashkari, Yury Goltsev, Sedide Ozturk, Garry P. Nolan. ebi.ac.uk. May 7, 2020.

The authors demonstrate split-pool barcoding for protein and targeted RNA measurements in cell lines, human blood-cell material and mouse cells. Large theoretical barcode capacity is distinct from measured event recovery. Uneven RNA detection, cell losses, exclusions, doublets and source discrepancies limit interpretation; no clinical or UAP validation follows.

Complete supplied main and correction text; partial supplemental visuals
PaperS7598

TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis

Reema Baskar, Harris G Fienberg, Zumana Khair, Patricia Favaro, Sam Kimmey, Douglas R Green, Garry P Nolan, Sylvia Plevritis, Sean C Bendall. ebi.ac.uk. November 8, 2019.

This cultured-cell study examines variation in resistance to TRAIL-induced apoptosis. Responses differ across cell lines, and no universal resistant signaling state emerged. Reviewers questioned replication, causality and selected-marker diversity; the revised paper and small surviving fractions retain those limits.

Complete supplied main text and qualified apparatus reviewed
PaperS7613

Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation

Xianting Ding, Peter O Krutzik, Amir Ali Ghaffari, Yixiu Zhaozhi, Daniel Miranda Jr, Genhong Cheng, Chih-Ming Ho, Garry P Nolan, David Jesse Sanchez. ebi.ac.uk. September 9, 2019.

The authors connect antiviral treatment, infection and ribosomal signaling in selected cell assays and a short mouse model. Timing, inadequate low-dose response, broad effects at higher doses, declining viability and delayed animal results qualify the mechanism. These findings do not demonstrate treatment benefit or safety in people.

Complete supplied main and meaningful images; raw study unreviewed

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach